Drugs Made In America Acquisition (DMIIR) Non-Current Assets (2024 - 2025)

Drugs Made In America Acquisition's (DMIIR) quarterly Non-Current Assets came in at $504.9 million in Q4 2025, up 643545.94% year-on-year from N/an in Q4 2024, and up 0.96% on a QoQ basis from $500.1 million in Q3 2025.

Drugs Made In America Acquisition (DMIIR) Non-Current Assets (2024 - 2025) Analysis & Trends

Drugs Made In America Acquisition (DMIIR) has 2 years of Non-Current Assets data on file, last reported at $504.9 million in Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 643545.94% year-over-year to $504.9 million in Q4 2025; TTM through Dec 2025 was $504.9 million, a 643545.94% increase from a year earlier, with the FY2025 full-year figure at $504.9 million, up 643545.94% from the prior year.
  • Non-Current Assets for Q4 2025 stood at $504.9 million, up from $500.1 million in the prior quarter.
  • Over the last five years, Non-Current Assets for DMIIR reached as high as $504.9 million in Q4 2025 and fell as low as $78449.0 in Q4 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 EQV Ventures Acquisition 480.75 Mn 480.75 Mn - 472.84 Mn
2 Agriculture & Natural Solutions Acquisition 393.29 Mn 393.29 Mn - 365.97 Mn
3 Berto Acquisition 314.56 Mn 314.35 Mn - 311.36 Mn
4 GP-Act III Acquisition 313.66 Mn 313.66 Mn - 309.18 Mn
5 Centurion Acquisition 311.65 Mn 311.65 Mn - 310.90 Mn
6 Republic Digital Acquisition 310.50 Mn 309.63 Mn - 310.77 Mn
7 Siddhi Acquisition Corp (Cayman Islands) 288.97 Mn 288.97 Mn - 288.44 Mn
8 K&F Growth Acquisition 283.42 Mn 283.42 Mn - 299.88 Mn
9 Bold Eagle Acquisition 275.29 Mn 275.29 Mn - 272.15 Mn
10 Drugs Made In America Acquisition - - - 504.93 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 504.93 Mn
Sep 30, 2025 500.11 Mn
Dec 31, 2024 78,449.00